Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Chandan HealthcareNSE:CHANDAN -4.01%17 PB Ratio is 4.09 as of Aug. 08, 2026, which is 14% below its 10-year median of 4.75. GuruFocus rates NSE:CHANDAN with a GF Score™ of 17/100. The stock has 4 warning signs investors should review. Among 195 Medical Diagnostics & Research companies, Chandan Healthcare ranks worse than 73.33% on this metric.
Chandan Healthcare Ltd stock PB Ratio (=4.07) is close to 1-year low of 4.07.
The historical rank and industry rank for Chandan Healthcare's PB Ratio or its related term are showing as below:
NSE:CHANDAN'
s PB Ratio Range Over the Past 10 Years
Min: 3.44 Med: 4.75 Max: 8.4
Current: 3.91
During the past 4 years, Chandan Healthcare's highest PB Ratio was 8.40. The lowest was 3.44. And the median was 4.75.
NSE:CHANDAN's PB Ratio is ranked worse than 73.33% of 195
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.11
vs NSE:CHANDAN: 3.91
During the past 12 months, Chandan Healthcare's average Book Value Per Share Growth Rate was 197.90% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 72.20% per year.
During the past 4 years, the highest 3-Year average Book Value Per Share Growth Rate of Chandan Healthcare was 72.20% per year. The lowest was 72.20% per year. And the median was 72.20% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Chandan Healthcare PB Ratio Related Terms
Chandan Healthcare PB Ratio Historical Data
* Premium members only.
The historical data trend for Chandan Healthcare's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:CHANDAN vs TMO, DHR, IDXX: PB Ratio Comparison
For the Diagnostics & Research subindustry, Chandan Healthcare's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chandan Healthcare PB Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Chandan Healthcare's PB Ratio distribution charts can be found below:
* The bar in red indicates where Chandan Healthcare's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Chandan Healthcare (NSE:CHANDAN) has a PB Ratio of 4.09 as of Aug. 08, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Chandan Healthcare and its competitors. This is 14% below median its historical median of 4.75. Over the past decade, Chandan Healthcare's PB Ratio has ranged from 3.44 to 8.40. According to the industry distribution chart, Chandan Healthcare ranks #143 out of 195 companies in the Medical Diagnostics & Research industry, placing it in the top 73.3%.
Is Chandan Healthcare's PB Ratio too high?
Chandan Healthcare's current PB Ratio of 4.09 is 14% below median its 10-year median of 4.75. Over the past 10 years, this metric has ranged from a low of 3.44 to a high of 8.40. The Medical Diagnostics & Research industry median PB Ratio is 2.11. Chandan Healthcare's value of 4.09 is 93.8% above this industry median. Based on the distribution chart, Chandan Healthcare ranks #143 out of 195 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Chandan Healthcare has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Chandan Healthcare's PB Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Chandan Healthcare ranks #143 out of 195 companies for PB Ratio. This places Chandan Healthcare in the lower half of its industry. The industry median PB Ratio is 2.11. Chandan Healthcare's value of 4.09 is 93.8% above this benchmark. Historically, Chandan Healthcare's own PB Ratio has ranged from 3.44 to 8.40 over the past decade. While the company's 10-year median is 4.75 vs. the industry median of 2.11, Chandan Healthcare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Diagnostics & Research company?
The median PB Ratio among Medical Diagnostics & Research companies is 2.11, based on 195 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chandan Healthcare's current PB Ratio of 4.09 is 93.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Chandan Healthcare and its competitors. For the Medical Diagnostics & Research industry, the median PB Ratio is 2.11 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chandan Healthcare's current PB Ratio is 4.09, which is 14% below median its own 10-year median of 4.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chandan Healthcare stock overvalued right now?
Chandan Healthcare (NSE:CHANDAN) has a current PB Ratio of 4.09. The current PB Ratio is 4.09, which is 14% below median its 10-year median of 4.75 and 93.8% above the Medical Diagnostics & Research industry median of 2.11. Chandan Healthcare's overall GF Score™ is 17/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Chandan Healthcare (NSE:CHANDAN), the current PB Ratio is 4.09 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Chandan Healthcare Ltd operates laboratories that offer comprehensive pathological investigations. Its services encompass biochemistry, hematology, histopathology, microbiology, and immunology. Additionally, it provide an extensive array of radiology services, including CT scans, X-rays, and MRIs. The company operates single reportable business segment that is Diagnostics Services.
17GF Score
Get the complete analysis for NSE:CHANDAN
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:CHANDAN has been successfully added to your 
